SCHEMBL11946282

SCHEMBL11946282

CC1(COc2c(N3CCN(S(=O)(=O)Cc4ccc5c(c4)NCCO5)CC3)cnn(-c3cc(F)cc(F)c3)c2=O)CC1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 2/20 0.35
▸ MAPT P10636 1/20 0.34
▸ POLB P06746 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ PPARG P37231 1/20 0.32
▸ NCOA2 Q15596 1/20 0.32
▸ NCOA1 Q15788 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ NCOA3 Q9Y6Q9 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ HTR1A P08908 1/20 0.30
▸ HTR1D P28221 1/20 0.30
▸ HTR1B P28222 1/20 0.30
▸ SLC6A4 P31645 1/20 0.30
▸ NR3C1 P04150 1/20 0.30
▸ NR3C2 P08235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945729 0.94 PIK3CA (0.36) MMP13MAPTPOLBCYP3A4CYP2C19
SCHEMBL11946281 0.90 HTR1A (0.40) POLBHTR1AHTR1DHTR1BSLC6A4
SCHEMBL11945730 0.88 MAPT (0.32) MMP13MAPTPOLBCYP3A4CYP2C19
SCHEMBL11945734 0.86 MAPT (0.33) MMP13MAPTPOLBCYP3A4CYP2C19
SCHEMBL17057858 0.86 MAPT (0.33) MMP13MAPTPOLBCYP3A4CYP2C19
SCHEMBL11945727 0.86 CXCR3 (0.32) MAPTPOLBCYP3A4CYP2C19PPARG
SCHEMBL11945640 0.85 MAPT (0.40) MMP13MAPTPOLBCYP3A4CYP2C19
SCHEMBL11945350 0.85 MAPT (0.39) MMP13MAPTPOLBCYP3A4CYP2C19
SCHEMBL11946396 0.84 MAPT (0.41) MMP13MAPTPOLBCYP3A4CYP2C19
SCHEMBL11945630 0.84 MAPT (0.37) MMP13MAPTPOLBCYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MMP13 3237/4885MAPT 2295/4885POLB 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback